Savara Inc

Savara’s MOLBREEVI BLA resubmission and priority‑review request spark analyst upgrades and bullish market sentiment, signaling a potential rapid FDA approval for a life‑saving rare‑lung therapy.

Savara Inc. unlocks all warrants, options and pre‑funded warrants on Dec 9, 2025, boosting liquidity, conversion pressure and capital‑raising potential for its rare‑disease pipeline.

Savara Inc., a clinical-stage biotechnology company, faces a critical November 7 deadline in a securities class action lawsuit alleging the company misled investors about its MOLBREEVI Biologics License Application, resulting in a 31% decline in sha…

Savara Inc faces regulatory hurdles with the FDA over its respiratory asset, MOLBREEVI, requiring additional manufacturing data and a meeting to address deficiencies in its marketing application.

Savara Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for rare respiratory diseases, with a strong global presence and commitment to improving patient outcomes.